Moderna, BioNTech Rally Stalls Ahead of CDC Meeting on Boosters

Bloomberg2021-08-30

(Bloomberg) -- The huge rally for Covid-19 vaccine makers has stalled as Wall Street waits for the U.S Centers for Disease Control and Prevention to weigh in on whether Americans should get a third ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

StayHome
2021-08-31
StayHome
Booster shot will begin again later I guess …Pls like and comment. Thanks.
- Huathk:
  Gd
Rteo
2021-08-30
Rteo
Good good
RS142
2021-08-30
RS142
Good going
Kczx
2021-08-30
Kczx
Let’s go
qwertypoiu
2021-08-30
qwertypoiu
[得意]
- Kczx:
  Haha
TTTa
2021-08-30
TTTa
Like

发表看法

100

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2163885784?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-08-30 21:20","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2163885784","market":"us","top_or_hot":-1,"title":"Moderna, BioNTech Rally Stalls Ahead of CDC Meeting on Boosters","media":"Bloomberg","content":"<div>\n<p>(Bloomberg) -- The huge rally for Covid-19 vaccine makers has stalled as Wall Street waits for the U.S Centers for Disease Control and Prevention to weigh in on whether Americans should get a third ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-biontech-rally-stalls-ahead-103004269.html\">网页链接</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna, BioNTech Rally Stalls Ahead of CDC Meeting on Boosters</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna, BioNTech Rally Stalls Ahead of CDC Meeting on Boosters\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-30 21:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-biontech-rally-stalls-ahead-103004269.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- The huge rally for Covid-19 vaccine makers has stalled as Wall Street waits for the U.S Centers for Disease Control and Prevention to weigh in on whether Americans should get a third ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-biontech-rally-stalls-ahead-103004269.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNTX","symbol_name":"BioNTech SE","start_time":0,"source_url":"https://finance.yahoo.com/news/moderna-biontech-rally-stalls-ahead-103004269.html","article_id":"2163885784","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2163885784","pubTimestamp":1630329604,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"(Bloomberg) -- The huge rally for Covid-19 vaccine makers has stalled as Wall Street waits for the U","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞","MRNA":"Moderna, Inc."},"translate_title":"现代生物技术公司在疾控中心助推器会议前举行集会","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTX":0.9,"MRNA":0.9,"PFE":0.9},"content_text":"(Bloomberg) -- The huge rally for Covid-19 vaccine makers has stalled as Wall Street waits for the U.S Centers for Disease Control and Prevention to weigh in on whether Americans should get a third shot.\nOn Monday, a meeting of outside advisers to the agency could finally give investors a sense of clarity.\nModerna Inc., which became the best performer in the S&P 500 Index after its stock price more than tripled this year, has slid 21% from its record high in early August. BioNTech SE, which has surged more than four-fold in 2021, has fallen almost as much over the past three weeks, while its U.S. partner, Pfizer Inc., is off more than 7% from its peak.\nThe retreat comes as the pace of the American inoculation campaign slows, leaving investors divided over how much growth to expect from the manufacturers. That rift has only deepened after President Joe Biden administration promised that booster shots will be made available to most Americans, which would be a major source of demand if regulators endorse that step.\nThe administration’s aim to push through new guidelines in late September, however, has been met with skepticism by some medical experts. The CDC as well as the U.S. Food and Drug Administration have to approve the plan before it can be implemented and that backing isn’t guaranteed.\nThat uncertainty is likely to continue fueling volatility in the stocks. Options imply that Moderna and BioNTech could move roughly 7% in either direction over the next week while Pfizer’s stock may move about 3%.\nMorgan Stanley’s Matthew Harrison is among Wall Street analysts who expect Biden’s plan to be backed by regulators. But but he remains equal weight on Moderna and Pfizer because he doesn’t expect any major new vaccine orders in the near future, with an estimated 630 million of unused shots from the companies already purchased through 2022.\n“We do not expect any supply constraints for booster doses and do not expect the U.S. government to purchase additional mRNA vaccine doses for 2022 based on current demand or booster dose need,” Harrison wrote in a research note, referring to the technology used in both Moderna and Pfizer’s shots.\nAnalysts with Goldman Sachs Group Inc. are more bullish. The bank has a buy rating on Moderna, estimating that its shot could drive $36.2 billion of sales next year, some $15 billion more than Bloomberg’s consensus estimates. “We see upside to these numbers given supply and pricing dynamics,” said analyst Asad Haider.\nHe sees new records for Moderna and Pfizer if U.S. and other global regulators endorse the receipt of a third dose. He estimates that Moderna shares -- which closed Friday a $382.22 -- could top $600 if boosters become the norm, while Pfizer could trade as high as $61, up from $46.58 at the end of last week.  BioNTech already trades at best-case levels, he wrote.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":811750576,"gmtCreate":1630361271295,"gmtModify":1704958948945,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"htmlText":"Booster shot will begin again later I guess …Pls like and comment. Thanks.&nbsp;","listText":"Booster shot will begin again later I guess …Pls like and comment. Thanks.&nbsp;","text":"Booster shot will begin again later I guess …Pls like and comment. Thanks.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/811750576","repostId":2163885784,"repostType":4,"repost":{"id":"2163885784","kind":"news","pubTimestamp":1630329604,"share":"https://www.laohu8.com/m/news/2163885784?lang=&edition=full","pubTime":"2021-08-30 21:20","market":"us","language":"en","title":"Moderna, BioNTech Rally Stalls Ahead of CDC Meeting on Boosters","url":"https://stock-news.laohu8.com/highlight/detail?id=2163885784","media":"Bloomberg","summary":"(Bloomberg) -- The huge rally for Covid-19 vaccine makers has stalled as Wall Street waits for the U","content":"<p>(Bloomberg) -- The huge rally for Covid-19 vaccine makers has stalled as Wall Street waits for the U.S Centers for Disease Control and Prevention to weigh in on whether Americans should get a third shot.</p>\n<p>On Monday, a meeting of outside advisers to the agency could finally give investors a sense of clarity.</p>\n<p>Moderna Inc., which became the best performer in the S&amp;P 500 Index after its stock price more than tripled this year, has slid 21% from its record high in early August. <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, which has surged more than four-fold in 2021, has fallen almost as much over the past three weeks, while its U.S. partner, Pfizer Inc., is off more than 7% from its peak.</p>\n<p>The retreat comes as the pace of the American inoculation campaign slows, leaving investors divided over how much growth to expect from the manufacturers. That rift has only deepened after President Joe Biden administration promised that booster shots will be made available to most Americans, which would be a major source of demand if regulators endorse that step.</p>\n<p>The administration’s aim to push through new guidelines in late September, however, has been met with skepticism by some medical experts. The CDC as well as the U.S. Food and Drug Administration have to approve the plan before it can be implemented and that backing isn’t guaranteed.</p>\n<p>That uncertainty is likely to continue fueling volatility in the stocks. Options imply that Moderna and BioNTech could move roughly 7% in either direction over the next week while Pfizer’s stock may move about 3%.</p>\n<p><a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a>’s Matthew Harrison is among Wall Street analysts who expect Biden’s plan to be backed by regulators. But but he remains equal weight on Moderna and Pfizer because he doesn’t expect any major new vaccine orders in the near future, with an estimated 630 million of unused shots from the companies already purchased through 2022.</p>\n<p>“We do not expect any supply constraints for booster doses and do not expect the U.S. government to purchase additional mRNA vaccine doses for 2022 based on current demand or booster dose need,” Harrison wrote in a research note, referring to the technology used in both Moderna and Pfizer’s shots.</p>\n<p>Analysts with Goldman Sachs Group Inc. are more bullish. The bank has a buy rating on Moderna, estimating that its shot could drive $36.2 billion of sales next year, some $15 billion more than Bloomberg’s consensus estimates. “We see upside to these numbers given supply and pricing dynamics,” said analyst Asad Haider.</p>\n<p>He sees new records for Moderna and Pfizer if U.S. and other global regulators endorse the receipt of a third dose. He estimates that Moderna shares -- which closed Friday a $382.22 -- could top $600 if boosters become the norm, while Pfizer could trade as high as $61, up from $46.58 at the end of last week. &nbsp;BioNTech already trades at best-case levels, he wrote.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna, BioNTech Rally Stalls Ahead of CDC Meeting on Boosters</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna, BioNTech Rally Stalls Ahead of CDC Meeting on Boosters\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-30 21:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-biontech-rally-stalls-ahead-103004269.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- The huge rally for Covid-19 vaccine makers has stalled as Wall Street waits for the U.S Centers for Disease Control and Prevention to weigh in on whether Americans should get a third ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-biontech-rally-stalls-ahead-103004269.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc.","BNTX":"BioNTech SE"},"source_url":"https://finance.yahoo.com/news/moderna-biontech-rally-stalls-ahead-103004269.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2163885784","content_text":"(Bloomberg) -- The huge rally for Covid-19 vaccine makers has stalled as Wall Street waits for the U.S Centers for Disease Control and Prevention to weigh in on whether Americans should get a third shot.\nOn Monday, a meeting of outside advisers to the agency could finally give investors a sense of clarity.\nModerna Inc., which became the best performer in the S&P 500 Index after its stock price more than tripled this year, has slid 21% from its record high in early August. BioNTech SE, which has surged more than four-fold in 2021, has fallen almost as much over the past three weeks, while its U.S. partner, Pfizer Inc., is off more than 7% from its peak.\nThe retreat comes as the pace of the American inoculation campaign slows, leaving investors divided over how much growth to expect from the manufacturers. That rift has only deepened after President Joe Biden administration promised that booster shots will be made available to most Americans, which would be a major source of demand if regulators endorse that step.\nThe administration’s aim to push through new guidelines in late September, however, has been met with skepticism by some medical experts. The CDC as well as the U.S. Food and Drug Administration have to approve the plan before it can be implemented and that backing isn’t guaranteed.\nThat uncertainty is likely to continue fueling volatility in the stocks. Options imply that Moderna and BioNTech could move roughly 7% in either direction over the next week while Pfizer’s stock may move about 3%.\nMorgan Stanley’s Matthew Harrison is among Wall Street analysts who expect Biden’s plan to be backed by regulators. But but he remains equal weight on Moderna and Pfizer because he doesn’t expect any major new vaccine orders in the near future, with an estimated 630 million of unused shots from the companies already purchased through 2022.\n“We do not expect any supply constraints for booster doses and do not expect the U.S. government to purchase additional mRNA vaccine doses for 2022 based on current demand or booster dose need,” Harrison wrote in a research note, referring to the technology used in both Moderna and Pfizer’s shots.\nAnalysts with Goldman Sachs Group Inc. are more bullish. The bank has a buy rating on Moderna, estimating that its shot could drive $36.2 billion of sales next year, some $15 billion more than Bloomberg’s consensus estimates. “We see upside to these numbers given supply and pricing dynamics,” said analyst Asad Haider.\nHe sees new records for Moderna and Pfizer if U.S. and other global regulators endorse the receipt of a third dose. He estimates that Moderna shares -- which closed Friday a $382.22 -- could top $600 if boosters become the norm, while Pfizer could trade as high as $61, up from $46.58 at the end of last week.  BioNTech already trades at best-case levels, he wrote.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5737815,"gmtCreate":1630635800737,"gmtModify":1631891258680,"authorId":3573472992263411,"author":{"id":3573472992263411,"idStr":"3573472992263411","authorId":3573472992263411,"name":"Huathk","avatar":"https://static.tigerbbs.com/43c7168c646d9ea6805194ed0003f1cc","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":811750576,"type":1,"supId":0,"prevId":0,"content":"Gd","text":"Gd","html":"Gd"}],"langContent":"EN"},{"id":811480310,"gmtCreate":1630336306230,"gmtModify":1704958756851,"author":{"id":"3582595806100338","authorId":"3582595806100338","name":"Rteo","avatar":"https://static.tigerbbs.com/ba4c61a94c707cd25f18400b8cc52a4c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582595806100338","authorIdStr":"3582595806100338"},"htmlText":"Good good","listText":"Good good","text":"Good good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/811480310","repostId":2163885784,"repostType":4,"repost":{"id":"2163885784","kind":"news","pubTimestamp":1630329604,"share":"https://www.laohu8.com/m/news/2163885784?lang=&edition=full","pubTime":"2021-08-30 21:20","market":"us","language":"en","title":"Moderna, BioNTech Rally Stalls Ahead of CDC Meeting on Boosters","url":"https://stock-news.laohu8.com/highlight/detail?id=2163885784","media":"Bloomberg","summary":"(Bloomberg) -- The huge rally for Covid-19 vaccine makers has stalled as Wall Street waits for the U","content":"<p>(Bloomberg) -- The huge rally for Covid-19 vaccine makers has stalled as Wall Street waits for the U.S Centers for Disease Control and Prevention to weigh in on whether Americans should get a third shot.</p>\n<p>On Monday, a meeting of outside advisers to the agency could finally give investors a sense of clarity.</p>\n<p>Moderna Inc., which became the best performer in the S&amp;P 500 Index after its stock price more than tripled this year, has slid 21% from its record high in early August. <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, which has surged more than four-fold in 2021, has fallen almost as much over the past three weeks, while its U.S. partner, Pfizer Inc., is off more than 7% from its peak.</p>\n<p>The retreat comes as the pace of the American inoculation campaign slows, leaving investors divided over how much growth to expect from the manufacturers. That rift has only deepened after President Joe Biden administration promised that booster shots will be made available to most Americans, which would be a major source of demand if regulators endorse that step.</p>\n<p>The administration’s aim to push through new guidelines in late September, however, has been met with skepticism by some medical experts. The CDC as well as the U.S. Food and Drug Administration have to approve the plan before it can be implemented and that backing isn’t guaranteed.</p>\n<p>That uncertainty is likely to continue fueling volatility in the stocks. Options imply that Moderna and BioNTech could move roughly 7% in either direction over the next week while Pfizer’s stock may move about 3%.</p>\n<p><a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a>’s Matthew Harrison is among Wall Street analysts who expect Biden’s plan to be backed by regulators. But but he remains equal weight on Moderna and Pfizer because he doesn’t expect any major new vaccine orders in the near future, with an estimated 630 million of unused shots from the companies already purchased through 2022.</p>\n<p>“We do not expect any supply constraints for booster doses and do not expect the U.S. government to purchase additional mRNA vaccine doses for 2022 based on current demand or booster dose need,” Harrison wrote in a research note, referring to the technology used in both Moderna and Pfizer’s shots.</p>\n<p>Analysts with Goldman Sachs Group Inc. are more bullish. The bank has a buy rating on Moderna, estimating that its shot could drive $36.2 billion of sales next year, some $15 billion more than Bloomberg’s consensus estimates. “We see upside to these numbers given supply and pricing dynamics,” said analyst Asad Haider.</p>\n<p>He sees new records for Moderna and Pfizer if U.S. and other global regulators endorse the receipt of a third dose. He estimates that Moderna shares -- which closed Friday a $382.22 -- could top $600 if boosters become the norm, while Pfizer could trade as high as $61, up from $46.58 at the end of last week. &nbsp;BioNTech already trades at best-case levels, he wrote.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna, BioNTech Rally Stalls Ahead of CDC Meeting on Boosters</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna, BioNTech Rally Stalls Ahead of CDC Meeting on Boosters\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-30 21:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-biontech-rally-stalls-ahead-103004269.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- The huge rally for Covid-19 vaccine makers has stalled as Wall Street waits for the U.S Centers for Disease Control and Prevention to weigh in on whether Americans should get a third ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-biontech-rally-stalls-ahead-103004269.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc.","BNTX":"BioNTech SE"},"source_url":"https://finance.yahoo.com/news/moderna-biontech-rally-stalls-ahead-103004269.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2163885784","content_text":"(Bloomberg) -- The huge rally for Covid-19 vaccine makers has stalled as Wall Street waits for the U.S Centers for Disease Control and Prevention to weigh in on whether Americans should get a third shot.\nOn Monday, a meeting of outside advisers to the agency could finally give investors a sense of clarity.\nModerna Inc., which became the best performer in the S&P 500 Index after its stock price more than tripled this year, has slid 21% from its record high in early August. BioNTech SE, which has surged more than four-fold in 2021, has fallen almost as much over the past three weeks, while its U.S. partner, Pfizer Inc., is off more than 7% from its peak.\nThe retreat comes as the pace of the American inoculation campaign slows, leaving investors divided over how much growth to expect from the manufacturers. That rift has only deepened after President Joe Biden administration promised that booster shots will be made available to most Americans, which would be a major source of demand if regulators endorse that step.\nThe administration’s aim to push through new guidelines in late September, however, has been met with skepticism by some medical experts. The CDC as well as the U.S. Food and Drug Administration have to approve the plan before it can be implemented and that backing isn’t guaranteed.\nThat uncertainty is likely to continue fueling volatility in the stocks. Options imply that Moderna and BioNTech could move roughly 7% in either direction over the next week while Pfizer’s stock may move about 3%.\nMorgan Stanley’s Matthew Harrison is among Wall Street analysts who expect Biden’s plan to be backed by regulators. But but he remains equal weight on Moderna and Pfizer because he doesn’t expect any major new vaccine orders in the near future, with an estimated 630 million of unused shots from the companies already purchased through 2022.\n“We do not expect any supply constraints for booster doses and do not expect the U.S. government to purchase additional mRNA vaccine doses for 2022 based on current demand or booster dose need,” Harrison wrote in a research note, referring to the technology used in both Moderna and Pfizer’s shots.\nAnalysts with Goldman Sachs Group Inc. are more bullish. The bank has a buy rating on Moderna, estimating that its shot could drive $36.2 billion of sales next year, some $15 billion more than Bloomberg’s consensus estimates. “We see upside to these numbers given supply and pricing dynamics,” said analyst Asad Haider.\nHe sees new records for Moderna and Pfizer if U.S. and other global regulators endorse the receipt of a third dose. He estimates that Moderna shares -- which closed Friday a $382.22 -- could top $600 if boosters become the norm, while Pfizer could trade as high as $61, up from $46.58 at the end of last week.  BioNTech already trades at best-case levels, he wrote.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":811400805,"gmtCreate":1630334164207,"gmtModify":1704958698405,"author":{"id":"3574118564601995","authorId":"3574118564601995","name":"RS142","avatar":"https://static.tigerbbs.com/22d2d9b1f352da24e6ea75b557ac987a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3574118564601995","authorIdStr":"3574118564601995"},"htmlText":"Good going","listText":"Good going","text":"Good going","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/811400805","repostId":2163885784,"repostType":4,"repost":{"id":"2163885784","kind":"news","pubTimestamp":1630329604,"share":"https://www.laohu8.com/m/news/2163885784?lang=&edition=full","pubTime":"2021-08-30 21:20","market":"us","language":"en","title":"Moderna, BioNTech Rally Stalls Ahead of CDC Meeting on Boosters","url":"https://stock-news.laohu8.com/highlight/detail?id=2163885784","media":"Bloomberg","summary":"(Bloomberg) -- The huge rally for Covid-19 vaccine makers has stalled as Wall Street waits for the U","content":"<p>(Bloomberg) -- The huge rally for Covid-19 vaccine makers has stalled as Wall Street waits for the U.S Centers for Disease Control and Prevention to weigh in on whether Americans should get a third shot.</p>\n<p>On Monday, a meeting of outside advisers to the agency could finally give investors a sense of clarity.</p>\n<p>Moderna Inc., which became the best performer in the S&amp;P 500 Index after its stock price more than tripled this year, has slid 21% from its record high in early August. <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, which has surged more than four-fold in 2021, has fallen almost as much over the past three weeks, while its U.S. partner, Pfizer Inc., is off more than 7% from its peak.</p>\n<p>The retreat comes as the pace of the American inoculation campaign slows, leaving investors divided over how much growth to expect from the manufacturers. That rift has only deepened after President Joe Biden administration promised that booster shots will be made available to most Americans, which would be a major source of demand if regulators endorse that step.</p>\n<p>The administration’s aim to push through new guidelines in late September, however, has been met with skepticism by some medical experts. The CDC as well as the U.S. Food and Drug Administration have to approve the plan before it can be implemented and that backing isn’t guaranteed.</p>\n<p>That uncertainty is likely to continue fueling volatility in the stocks. Options imply that Moderna and BioNTech could move roughly 7% in either direction over the next week while Pfizer’s stock may move about 3%.</p>\n<p><a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a>’s Matthew Harrison is among Wall Street analysts who expect Biden’s plan to be backed by regulators. But but he remains equal weight on Moderna and Pfizer because he doesn’t expect any major new vaccine orders in the near future, with an estimated 630 million of unused shots from the companies already purchased through 2022.</p>\n<p>“We do not expect any supply constraints for booster doses and do not expect the U.S. government to purchase additional mRNA vaccine doses for 2022 based on current demand or booster dose need,” Harrison wrote in a research note, referring to the technology used in both Moderna and Pfizer’s shots.</p>\n<p>Analysts with Goldman Sachs Group Inc. are more bullish. The bank has a buy rating on Moderna, estimating that its shot could drive $36.2 billion of sales next year, some $15 billion more than Bloomberg’s consensus estimates. “We see upside to these numbers given supply and pricing dynamics,” said analyst Asad Haider.</p>\n<p>He sees new records for Moderna and Pfizer if U.S. and other global regulators endorse the receipt of a third dose. He estimates that Moderna shares -- which closed Friday a $382.22 -- could top $600 if boosters become the norm, while Pfizer could trade as high as $61, up from $46.58 at the end of last week. &nbsp;BioNTech already trades at best-case levels, he wrote.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna, BioNTech Rally Stalls Ahead of CDC Meeting on Boosters</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna, BioNTech Rally Stalls Ahead of CDC Meeting on Boosters\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-30 21:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-biontech-rally-stalls-ahead-103004269.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- The huge rally for Covid-19 vaccine makers has stalled as Wall Street waits for the U.S Centers for Disease Control and Prevention to weigh in on whether Americans should get a third ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-biontech-rally-stalls-ahead-103004269.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc.","BNTX":"BioNTech SE"},"source_url":"https://finance.yahoo.com/news/moderna-biontech-rally-stalls-ahead-103004269.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2163885784","content_text":"(Bloomberg) -- The huge rally for Covid-19 vaccine makers has stalled as Wall Street waits for the U.S Centers for Disease Control and Prevention to weigh in on whether Americans should get a third shot.\nOn Monday, a meeting of outside advisers to the agency could finally give investors a sense of clarity.\nModerna Inc., which became the best performer in the S&P 500 Index after its stock price more than tripled this year, has slid 21% from its record high in early August. BioNTech SE, which has surged more than four-fold in 2021, has fallen almost as much over the past three weeks, while its U.S. partner, Pfizer Inc., is off more than 7% from its peak.\nThe retreat comes as the pace of the American inoculation campaign slows, leaving investors divided over how much growth to expect from the manufacturers. That rift has only deepened after President Joe Biden administration promised that booster shots will be made available to most Americans, which would be a major source of demand if regulators endorse that step.\nThe administration’s aim to push through new guidelines in late September, however, has been met with skepticism by some medical experts. The CDC as well as the U.S. Food and Drug Administration have to approve the plan before it can be implemented and that backing isn’t guaranteed.\nThat uncertainty is likely to continue fueling volatility in the stocks. Options imply that Moderna and BioNTech could move roughly 7% in either direction over the next week while Pfizer’s stock may move about 3%.\nMorgan Stanley’s Matthew Harrison is among Wall Street analysts who expect Biden’s plan to be backed by regulators. But but he remains equal weight on Moderna and Pfizer because he doesn’t expect any major new vaccine orders in the near future, with an estimated 630 million of unused shots from the companies already purchased through 2022.\n“We do not expect any supply constraints for booster doses and do not expect the U.S. government to purchase additional mRNA vaccine doses for 2022 based on current demand or booster dose need,” Harrison wrote in a research note, referring to the technology used in both Moderna and Pfizer’s shots.\nAnalysts with Goldman Sachs Group Inc. are more bullish. The bank has a buy rating on Moderna, estimating that its shot could drive $36.2 billion of sales next year, some $15 billion more than Bloomberg’s consensus estimates. “We see upside to these numbers given supply and pricing dynamics,” said analyst Asad Haider.\nHe sees new records for Moderna and Pfizer if U.S. and other global regulators endorse the receipt of a third dose. He estimates that Moderna shares -- which closed Friday a $382.22 -- could top $600 if boosters become the norm, while Pfizer could trade as high as $61, up from $46.58 at the end of last week.  BioNTech already trades at best-case levels, he wrote.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":811522681,"gmtCreate":1630332976743,"gmtModify":1704958651671,"author":{"id":"4089856301721210","authorId":"4089856301721210","name":"Kczx","avatar":"https://static.tigerbbs.com/f4e2ec76e0922c883fecf5ff8b259010","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"4089856301721210","authorIdStr":"4089856301721210"},"htmlText":"Let’s go","listText":"Let’s go","text":"Let’s go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/811522681","repostId":2163885784,"repostType":4,"repost":{"id":"2163885784","kind":"news","pubTimestamp":1630329604,"share":"https://www.laohu8.com/m/news/2163885784?lang=&edition=full","pubTime":"2021-08-30 21:20","market":"us","language":"en","title":"Moderna, BioNTech Rally Stalls Ahead of CDC Meeting on Boosters","url":"https://stock-news.laohu8.com/highlight/detail?id=2163885784","media":"Bloomberg","summary":"(Bloomberg) -- The huge rally for Covid-19 vaccine makers has stalled as Wall Street waits for the U","content":"<p>(Bloomberg) -- The huge rally for Covid-19 vaccine makers has stalled as Wall Street waits for the U.S Centers for Disease Control and Prevention to weigh in on whether Americans should get a third shot.</p>\n<p>On Monday, a meeting of outside advisers to the agency could finally give investors a sense of clarity.</p>\n<p>Moderna Inc., which became the best performer in the S&amp;P 500 Index after its stock price more than tripled this year, has slid 21% from its record high in early August. <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, which has surged more than four-fold in 2021, has fallen almost as much over the past three weeks, while its U.S. partner, Pfizer Inc., is off more than 7% from its peak.</p>\n<p>The retreat comes as the pace of the American inoculation campaign slows, leaving investors divided over how much growth to expect from the manufacturers. That rift has only deepened after President Joe Biden administration promised that booster shots will be made available to most Americans, which would be a major source of demand if regulators endorse that step.</p>\n<p>The administration’s aim to push through new guidelines in late September, however, has been met with skepticism by some medical experts. The CDC as well as the U.S. Food and Drug Administration have to approve the plan before it can be implemented and that backing isn’t guaranteed.</p>\n<p>That uncertainty is likely to continue fueling volatility in the stocks. Options imply that Moderna and BioNTech could move roughly 7% in either direction over the next week while Pfizer’s stock may move about 3%.</p>\n<p><a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a>’s Matthew Harrison is among Wall Street analysts who expect Biden’s plan to be backed by regulators. But but he remains equal weight on Moderna and Pfizer because he doesn’t expect any major new vaccine orders in the near future, with an estimated 630 million of unused shots from the companies already purchased through 2022.</p>\n<p>“We do not expect any supply constraints for booster doses and do not expect the U.S. government to purchase additional mRNA vaccine doses for 2022 based on current demand or booster dose need,” Harrison wrote in a research note, referring to the technology used in both Moderna and Pfizer’s shots.</p>\n<p>Analysts with Goldman Sachs Group Inc. are more bullish. The bank has a buy rating on Moderna, estimating that its shot could drive $36.2 billion of sales next year, some $15 billion more than Bloomberg’s consensus estimates. “We see upside to these numbers given supply and pricing dynamics,” said analyst Asad Haider.</p>\n<p>He sees new records for Moderna and Pfizer if U.S. and other global regulators endorse the receipt of a third dose. He estimates that Moderna shares -- which closed Friday a $382.22 -- could top $600 if boosters become the norm, while Pfizer could trade as high as $61, up from $46.58 at the end of last week. &nbsp;BioNTech already trades at best-case levels, he wrote.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna, BioNTech Rally Stalls Ahead of CDC Meeting on Boosters</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna, BioNTech Rally Stalls Ahead of CDC Meeting on Boosters\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-30 21:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-biontech-rally-stalls-ahead-103004269.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- The huge rally for Covid-19 vaccine makers has stalled as Wall Street waits for the U.S Centers for Disease Control and Prevention to weigh in on whether Americans should get a third ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-biontech-rally-stalls-ahead-103004269.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc.","BNTX":"BioNTech SE"},"source_url":"https://finance.yahoo.com/news/moderna-biontech-rally-stalls-ahead-103004269.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2163885784","content_text":"(Bloomberg) -- The huge rally for Covid-19 vaccine makers has stalled as Wall Street waits for the U.S Centers for Disease Control and Prevention to weigh in on whether Americans should get a third shot.\nOn Monday, a meeting of outside advisers to the agency could finally give investors a sense of clarity.\nModerna Inc., which became the best performer in the S&P 500 Index after its stock price more than tripled this year, has slid 21% from its record high in early August. BioNTech SE, which has surged more than four-fold in 2021, has fallen almost as much over the past three weeks, while its U.S. partner, Pfizer Inc., is off more than 7% from its peak.\nThe retreat comes as the pace of the American inoculation campaign slows, leaving investors divided over how much growth to expect from the manufacturers. That rift has only deepened after President Joe Biden administration promised that booster shots will be made available to most Americans, which would be a major source of demand if regulators endorse that step.\nThe administration’s aim to push through new guidelines in late September, however, has been met with skepticism by some medical experts. The CDC as well as the U.S. Food and Drug Administration have to approve the plan before it can be implemented and that backing isn’t guaranteed.\nThat uncertainty is likely to continue fueling volatility in the stocks. Options imply that Moderna and BioNTech could move roughly 7% in either direction over the next week while Pfizer’s stock may move about 3%.\nMorgan Stanley’s Matthew Harrison is among Wall Street analysts who expect Biden’s plan to be backed by regulators. But but he remains equal weight on Moderna and Pfizer because he doesn’t expect any major new vaccine orders in the near future, with an estimated 630 million of unused shots from the companies already purchased through 2022.\n“We do not expect any supply constraints for booster doses and do not expect the U.S. government to purchase additional mRNA vaccine doses for 2022 based on current demand or booster dose need,” Harrison wrote in a research note, referring to the technology used in both Moderna and Pfizer’s shots.\nAnalysts with Goldman Sachs Group Inc. are more bullish. The bank has a buy rating on Moderna, estimating that its shot could drive $36.2 billion of sales next year, some $15 billion more than Bloomberg’s consensus estimates. “We see upside to these numbers given supply and pricing dynamics,” said analyst Asad Haider.\nHe sees new records for Moderna and Pfizer if U.S. and other global regulators endorse the receipt of a third dose. He estimates that Moderna shares -- which closed Friday a $382.22 -- could top $600 if boosters become the norm, while Pfizer could trade as high as $61, up from $46.58 at the end of last week.  BioNTech already trades at best-case levels, he wrote.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":811584446,"gmtCreate":1630332356785,"gmtModify":1704958625625,"author":{"id":"3580292313126530","authorId":"3580292313126530","name":"qwertypoiu","avatar":"https://static.tigerbbs.com/4643e13a65913a0821a12b3be7c42d52","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3580292313126530","authorIdStr":"3580292313126530"},"htmlText":"[得意]&nbsp;","listText":"[得意]&nbsp;","text":"[得意]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/811584446","repostId":2163885784,"repostType":4,"repost":{"id":"2163885784","kind":"news","pubTimestamp":1630329604,"share":"https://www.laohu8.com/m/news/2163885784?lang=&edition=full","pubTime":"2021-08-30 21:20","market":"us","language":"en","title":"Moderna, BioNTech Rally Stalls Ahead of CDC Meeting on Boosters","url":"https://stock-news.laohu8.com/highlight/detail?id=2163885784","media":"Bloomberg","summary":"(Bloomberg) -- The huge rally for Covid-19 vaccine makers has stalled as Wall Street waits for the U","content":"<p>(Bloomberg) -- The huge rally for Covid-19 vaccine makers has stalled as Wall Street waits for the U.S Centers for Disease Control and Prevention to weigh in on whether Americans should get a third shot.</p>\n<p>On Monday, a meeting of outside advisers to the agency could finally give investors a sense of clarity.</p>\n<p>Moderna Inc., which became the best performer in the S&amp;P 500 Index after its stock price more than tripled this year, has slid 21% from its record high in early August. <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, which has surged more than four-fold in 2021, has fallen almost as much over the past three weeks, while its U.S. partner, Pfizer Inc., is off more than 7% from its peak.</p>\n<p>The retreat comes as the pace of the American inoculation campaign slows, leaving investors divided over how much growth to expect from the manufacturers. That rift has only deepened after President Joe Biden administration promised that booster shots will be made available to most Americans, which would be a major source of demand if regulators endorse that step.</p>\n<p>The administration’s aim to push through new guidelines in late September, however, has been met with skepticism by some medical experts. The CDC as well as the U.S. Food and Drug Administration have to approve the plan before it can be implemented and that backing isn’t guaranteed.</p>\n<p>That uncertainty is likely to continue fueling volatility in the stocks. Options imply that Moderna and BioNTech could move roughly 7% in either direction over the next week while Pfizer’s stock may move about 3%.</p>\n<p><a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a>’s Matthew Harrison is among Wall Street analysts who expect Biden’s plan to be backed by regulators. But but he remains equal weight on Moderna and Pfizer because he doesn’t expect any major new vaccine orders in the near future, with an estimated 630 million of unused shots from the companies already purchased through 2022.</p>\n<p>“We do not expect any supply constraints for booster doses and do not expect the U.S. government to purchase additional mRNA vaccine doses for 2022 based on current demand or booster dose need,” Harrison wrote in a research note, referring to the technology used in both Moderna and Pfizer’s shots.</p>\n<p>Analysts with Goldman Sachs Group Inc. are more bullish. The bank has a buy rating on Moderna, estimating that its shot could drive $36.2 billion of sales next year, some $15 billion more than Bloomberg’s consensus estimates. “We see upside to these numbers given supply and pricing dynamics,” said analyst Asad Haider.</p>\n<p>He sees new records for Moderna and Pfizer if U.S. and other global regulators endorse the receipt of a third dose. He estimates that Moderna shares -- which closed Friday a $382.22 -- could top $600 if boosters become the norm, while Pfizer could trade as high as $61, up from $46.58 at the end of last week. &nbsp;BioNTech already trades at best-case levels, he wrote.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna, BioNTech Rally Stalls Ahead of CDC Meeting on Boosters</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna, BioNTech Rally Stalls Ahead of CDC Meeting on Boosters\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-30 21:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-biontech-rally-stalls-ahead-103004269.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- The huge rally for Covid-19 vaccine makers has stalled as Wall Street waits for the U.S Centers for Disease Control and Prevention to weigh in on whether Americans should get a third ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-biontech-rally-stalls-ahead-103004269.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc.","BNTX":"BioNTech SE"},"source_url":"https://finance.yahoo.com/news/moderna-biontech-rally-stalls-ahead-103004269.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2163885784","content_text":"(Bloomberg) -- The huge rally for Covid-19 vaccine makers has stalled as Wall Street waits for the U.S Centers for Disease Control and Prevention to weigh in on whether Americans should get a third shot.\nOn Monday, a meeting of outside advisers to the agency could finally give investors a sense of clarity.\nModerna Inc., which became the best performer in the S&P 500 Index after its stock price more than tripled this year, has slid 21% from its record high in early August. BioNTech SE, which has surged more than four-fold in 2021, has fallen almost as much over the past three weeks, while its U.S. partner, Pfizer Inc., is off more than 7% from its peak.\nThe retreat comes as the pace of the American inoculation campaign slows, leaving investors divided over how much growth to expect from the manufacturers. That rift has only deepened after President Joe Biden administration promised that booster shots will be made available to most Americans, which would be a major source of demand if regulators endorse that step.\nThe administration’s aim to push through new guidelines in late September, however, has been met with skepticism by some medical experts. The CDC as well as the U.S. Food and Drug Administration have to approve the plan before it can be implemented and that backing isn’t guaranteed.\nThat uncertainty is likely to continue fueling volatility in the stocks. Options imply that Moderna and BioNTech could move roughly 7% in either direction over the next week while Pfizer’s stock may move about 3%.\nMorgan Stanley’s Matthew Harrison is among Wall Street analysts who expect Biden’s plan to be backed by regulators. But but he remains equal weight on Moderna and Pfizer because he doesn’t expect any major new vaccine orders in the near future, with an estimated 630 million of unused shots from the companies already purchased through 2022.\n“We do not expect any supply constraints for booster doses and do not expect the U.S. government to purchase additional mRNA vaccine doses for 2022 based on current demand or booster dose need,” Harrison wrote in a research note, referring to the technology used in both Moderna and Pfizer’s shots.\nAnalysts with Goldman Sachs Group Inc. are more bullish. The bank has a buy rating on Moderna, estimating that its shot could drive $36.2 billion of sales next year, some $15 billion more than Bloomberg’s consensus estimates. “We see upside to these numbers given supply and pricing dynamics,” said analyst Asad Haider.\nHe sees new records for Moderna and Pfizer if U.S. and other global regulators endorse the receipt of a third dose. He estimates that Moderna shares -- which closed Friday a $382.22 -- could top $600 if boosters become the norm, while Pfizer could trade as high as $61, up from $46.58 at the end of last week.  BioNTech already trades at best-case levels, he wrote.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5695792,"gmtCreate":1630332970259,"gmtModify":1631890153247,"authorId":4089856301721210,"author":{"id":4089856301721210,"idStr":"4089856301721210","authorId":4089856301721210,"name":"Kczx","avatar":"https://static.tigerbbs.com/f4e2ec76e0922c883fecf5ff8b259010","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":811584446,"type":1,"supId":0,"prevId":0,"content":"Haha","text":"Haha","html":"Haha"}],"langContent":"CN"},{"id":811582427,"gmtCreate":1630332286369,"gmtModify":1704958622496,"author":{"id":"3567378212600527","authorId":"3567378212600527","name":"TTTa","avatar":"https://static.tigerbbs.com/2cadde203f51041e2e0dceaa2f0097f2","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3567378212600527","authorIdStr":"3567378212600527"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/811582427","repostId":2163885784,"repostType":4,"repost":{"id":"2163885784","kind":"news","pubTimestamp":1630329604,"share":"https://www.laohu8.com/m/news/2163885784?lang=&edition=full","pubTime":"2021-08-30 21:20","market":"us","language":"en","title":"Moderna, BioNTech Rally Stalls Ahead of CDC Meeting on Boosters","url":"https://stock-news.laohu8.com/highlight/detail?id=2163885784","media":"Bloomberg","summary":"(Bloomberg) -- The huge rally for Covid-19 vaccine makers has stalled as Wall Street waits for the U","content":"<p>(Bloomberg) -- The huge rally for Covid-19 vaccine makers has stalled as Wall Street waits for the U.S Centers for Disease Control and Prevention to weigh in on whether Americans should get a third shot.</p>\n<p>On Monday, a meeting of outside advisers to the agency could finally give investors a sense of clarity.</p>\n<p>Moderna Inc., which became the best performer in the S&amp;P 500 Index after its stock price more than tripled this year, has slid 21% from its record high in early August. <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, which has surged more than four-fold in 2021, has fallen almost as much over the past three weeks, while its U.S. partner, Pfizer Inc., is off more than 7% from its peak.</p>\n<p>The retreat comes as the pace of the American inoculation campaign slows, leaving investors divided over how much growth to expect from the manufacturers. That rift has only deepened after President Joe Biden administration promised that booster shots will be made available to most Americans, which would be a major source of demand if regulators endorse that step.</p>\n<p>The administration’s aim to push through new guidelines in late September, however, has been met with skepticism by some medical experts. The CDC as well as the U.S. Food and Drug Administration have to approve the plan before it can be implemented and that backing isn’t guaranteed.</p>\n<p>That uncertainty is likely to continue fueling volatility in the stocks. Options imply that Moderna and BioNTech could move roughly 7% in either direction over the next week while Pfizer’s stock may move about 3%.</p>\n<p><a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a>’s Matthew Harrison is among Wall Street analysts who expect Biden’s plan to be backed by regulators. But but he remains equal weight on Moderna and Pfizer because he doesn’t expect any major new vaccine orders in the near future, with an estimated 630 million of unused shots from the companies already purchased through 2022.</p>\n<p>“We do not expect any supply constraints for booster doses and do not expect the U.S. government to purchase additional mRNA vaccine doses for 2022 based on current demand or booster dose need,” Harrison wrote in a research note, referring to the technology used in both Moderna and Pfizer’s shots.</p>\n<p>Analysts with Goldman Sachs Group Inc. are more bullish. The bank has a buy rating on Moderna, estimating that its shot could drive $36.2 billion of sales next year, some $15 billion more than Bloomberg’s consensus estimates. “We see upside to these numbers given supply and pricing dynamics,” said analyst Asad Haider.</p>\n<p>He sees new records for Moderna and Pfizer if U.S. and other global regulators endorse the receipt of a third dose. He estimates that Moderna shares -- which closed Friday a $382.22 -- could top $600 if boosters become the norm, while Pfizer could trade as high as $61, up from $46.58 at the end of last week. &nbsp;BioNTech already trades at best-case levels, he wrote.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna, BioNTech Rally Stalls Ahead of CDC Meeting on Boosters</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna, BioNTech Rally Stalls Ahead of CDC Meeting on Boosters\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-30 21:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-biontech-rally-stalls-ahead-103004269.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- The huge rally for Covid-19 vaccine makers has stalled as Wall Street waits for the U.S Centers for Disease Control and Prevention to weigh in on whether Americans should get a third ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-biontech-rally-stalls-ahead-103004269.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc.","BNTX":"BioNTech SE"},"source_url":"https://finance.yahoo.com/news/moderna-biontech-rally-stalls-ahead-103004269.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2163885784","content_text":"(Bloomberg) -- The huge rally for Covid-19 vaccine makers has stalled as Wall Street waits for the U.S Centers for Disease Control and Prevention to weigh in on whether Americans should get a third shot.\nOn Monday, a meeting of outside advisers to the agency could finally give investors a sense of clarity.\nModerna Inc., which became the best performer in the S&P 500 Index after its stock price more than tripled this year, has slid 21% from its record high in early August. BioNTech SE, which has surged more than four-fold in 2021, has fallen almost as much over the past three weeks, while its U.S. partner, Pfizer Inc., is off more than 7% from its peak.\nThe retreat comes as the pace of the American inoculation campaign slows, leaving investors divided over how much growth to expect from the manufacturers. That rift has only deepened after President Joe Biden administration promised that booster shots will be made available to most Americans, which would be a major source of demand if regulators endorse that step.\nThe administration’s aim to push through new guidelines in late September, however, has been met with skepticism by some medical experts. The CDC as well as the U.S. Food and Drug Administration have to approve the plan before it can be implemented and that backing isn’t guaranteed.\nThat uncertainty is likely to continue fueling volatility in the stocks. Options imply that Moderna and BioNTech could move roughly 7% in either direction over the next week while Pfizer’s stock may move about 3%.\nMorgan Stanley’s Matthew Harrison is among Wall Street analysts who expect Biden’s plan to be backed by regulators. But but he remains equal weight on Moderna and Pfizer because he doesn’t expect any major new vaccine orders in the near future, with an estimated 630 million of unused shots from the companies already purchased through 2022.\n“We do not expect any supply constraints for booster doses and do not expect the U.S. government to purchase additional mRNA vaccine doses for 2022 based on current demand or booster dose need,” Harrison wrote in a research note, referring to the technology used in both Moderna and Pfizer’s shots.\nAnalysts with Goldman Sachs Group Inc. are more bullish. The bank has a buy rating on Moderna, estimating that its shot could drive $36.2 billion of sales next year, some $15 billion more than Bloomberg’s consensus estimates. “We see upside to these numbers given supply and pricing dynamics,” said analyst Asad Haider.\nHe sees new records for Moderna and Pfizer if U.S. and other global regulators endorse the receipt of a third dose. He estimates that Moderna shares -- which closed Friday a $382.22 -- could top $600 if boosters become the norm, while Pfizer could trade as high as $61, up from $46.58 at the end of last week.  BioNTech already trades at best-case levels, he wrote.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":100,"commentSize":21,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2163885784"}